| Literature DB >> 36172282 |
Galina Sufianova1, Ilgiz Gareev2, Ozal Beylerli2, Jianing Wu3, Alina Shumadalova4, Albert Sufianov2,5, Xin Chen6, Shiguang Zhao3,6.
Abstract
Polyphenols are secondary plant metabolites or organic compounds synthesized by them. In other words, these are molecules that are found in plants. Due to the wide variety of polyphenols and the plants in which they are found, these compounds are divided according to the source of origin, the function of the polyphenols, and their chemical structure; where the main ones are flavonoids. All the beneficial properties of polyphenols have not yet been studied, since this group of substances is very extensive and diverse. However, most polyphenols are known to be powerful antioxidants and have anti-inflammatory effects. Polyphenols help fight cell damage caused by free radicals and immune system components. In particular, polyphenols are credited with a preventive effect that helps protect the body from certain forms of cancer. The onset and progression of tumors may be related directly to oxidative stress, or inflammation. These processes can increase the amount of DNA damage and lead to loss of control over cell division. A number of studies have shown that oxidative stress uncontrolled by antioxidants or an uncontrolled and prolonged inflammatory process increases the risk of developing sarcoma, melanoma, and breast, lung, liver, and prostate cancer. Therefore, a more in-depth study of the effect of polyphenolic compounds on certain signaling pathways that determine the complex cascade of oncogenesis is a promising direction in the search for new methods for the prevention and treatment of tumors.Entities:
Keywords: anti-tumor therapy; flavonoids; oncogenesis; polyphenols; prevention; signal pathways
Year: 2022 PMID: 36172282 PMCID: PMC9512088 DOI: 10.3389/fcell.2022.1011435
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Main groups of natural polyphenolic compounds (A–B). (A) Phenolic compounds (polyphenols) constitute one of the most numerous and widespread groups of plant substances. The structure of polyphenols can contain both simple molecules (phenolic acids) and highly polymerized compounds (condensed tannins). (B) It should be noted that the main share here falls on flavonoids. Structural changes in the rings subdivide flavonoids into several families: flavonols, flavones, flavanols, isoflavones, anthocyanins, etc. These families are often found in the form of glycosides. Various variations of flavonoids are linked by a common biosynthesis.
Results of some preclinical and clinical experiments on the study of the therapeutic effect of polyphenols in tumors.
| Polyphenol | Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|---|
| PEBP | Breast Cancer |
| FOXO1 and miR-145 | Inhibits breast cancer development and progression |
|
| EGCG | TNBC |
| PRODH and alpha-SMA | Sensitizes TNBC tumor cells to clinical therapeutic drugs. Inhibits tumor growth and prevents tumor cell metastasis |
|
| APG-157 | Oral cancer | A double-blind, randomized, placebo-controlled, phase I clinical trial | IL-1β, IL-6, and IL-8 | Increases expression of genes associated with differentiation and T-cell recruitment to the tumor microenvironment |
|
| Polyphenols of green and black tea | Prostate cancer | Open label, randomized, phase II trial | Ki67, apoptosis Bcl-2, Bax, Tunel, NF-κB, and 8OHdG | Anti-inflammatory effect. Promotes tumor cells death. Decrease in serum PSA |
|
| Polyphenon E [a green tea polyphenol formulation primarily consisting of EGCG] | Bladder cancer | Multi-centered, randomized, double-blind, placebo-controlled, phase II trial | PCNA, MMP-2, clusterin, VEGF, p27, IGF-1, IGFBP-3 | Inhibits invasion, angiogenesis, tumor cells migration, and progression |
|
| AVP | Glioblastoma |
| NF-κB, IκB-α, TNF-α, TRAIL, caspase-3 and caspase-9 | Inhibitory effect on glioma cells: inhibits proliferation and enhances tumor cell apoptosis |
|
| Curcumin | Glioblastoma |
| ERK/MAPK pathway | Inhibits adverse psychological stress‐induced proliferation and invasion of tumor cells |
|
| NDGA | Medulloblastoma |
| Glutathione/glutathione disulfide | Induce oxidative stress, G2/M and S-G2/M cell cycle arrest, and tumor cells apoptosis |
|
| Polyphenol complex catechin:lysine 1:2 | Breast, pancreatic and colorectal cancer |
| JAK2/STAT3 and Wnt pathway | Antimigratory and pro-apoptotic effects |
|
| BPIS | Colorectal cancer |
| Akt, Cyclin B1, CDK1, and miR-149 | Increases the chemosensitivity, induce cell cycle arrest in G2/M phase |
|
TNBCs, triple-negative breast cancers; PEBP, polyphenol enriched blueberry preparation; EGCG, epigallocatechin-3-gallate; AVP, apocynum venetum polyphenol; NDGA, polyphenols α-mangostin and nordihydroguaiaretic acid; BPIS, polyphenol from foxtail millet bran; FOXO1, forkhead box protein O1; PRODH, proline dehydrogenase; alpha-SMA, smooth muscle alpha-actin; IL-1β, 6, 8, interleukin -1β, 6, 8; Ki-67, tissue immunostaining of proliferation apoptosis; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; NF-κB, nuclear and cytoplasmic nuclear factor kappa B; 8OHdG, 8-hydroxydeoxy-guanosine; PCNA, proliferating cell nuclear antigen; MMP-2, matrix metalloproteinase-2; VEGF, vascular endothelial growth factor; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein-3; IκB-α, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; TNF-α, tumor necrosis factor-alpha; TRAIL, tumor necrosis factor ligand superfamily member 10; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; JAK2, janus kinase 2; STAT3, signal transducer and activator of transcription 3; CDK1, cyclin-dependent kinase 1; PSA, prostate-specific antigen.
FIGURE 2Schematic representation of cell cycle regulation. The activating and inhibitory effect of some polyphenols [curcumin, resveratrol, apigenin, and epigallocatechin-3-gallate (EGCG)] on the cell cycle of a tumor cell was shown.
FIGURE 3A scheme of intracellular signal transduction is presented. The inhibitory effect of epigallocatechin-3-gallate (EGCG) on some protein kinase signaling pathways and transcription factors has been shown, as a complex of p65 and p50 subunits. Note: EGFR, Epidermal growth factor receptor; HER 2/3, Human epidermal growth factor receptor 2/3; PI3K, Phosphoinositide 3-kinases; PKC, Protein kinase C; Ras GTP, RAS guanosine triphosphate; NIK, NF-kappa-B-inducing kinase; MKK4, Mitogen-activated protein kinase kinase 4; MEK 1/2, Mitogen-activated protein kinase kinase 1/2; ERK 1/2, Extracellular signal-regulated kinase-1/2; JNK, c-Jun N-terminal Kinase; BAD, BCL2-associated agonist of cell death; PIP 2/3, Prolactin induced protein 2/3; Bcl-xL, B-cell lymphoma-extra large; IKK α, β, γ, Cytokine-responsive IkappaB kinase α, β, γ; IkBα, Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; Ub, Ubiquitin B; AP-1, Activator protein 1; MMP-9, Matrix metallopeptidase 9; COX-2, cyclooxygenase 2; Bcl-2, B-cell lymphoma-2; c-FLIP, Cellular FLICE-like inhibitory protein; IAP 1/2, Inhibitor of apoptosis 1/2.
FIGURE 4Apoptosis induction by some natural polyphenols. There are two main ways of apoptosis: 1. Apoptosis is activated by the interaction of specific ligands on the cell surface with receptor proteins containing “death domains”; and 2. The mitochondrial pathway of apoptosis begins with the collapse of the mitochondrial membrane potential and is accompanied by the release of cytochrome C from the mitochondrial intermembrane space into the cell cytoplasm. The vast experimental material obtained so far indicates that some natural polyphenols (epigallocatechin-3-gallate (EGCG), apigenin, genistein, luteolin, resveratrol, curcumin, and anthocyanin) have an apoptogenic effect using a variety of cellular targets. Note: BAX, Bcl-2 associated X-protein; Bcl-2, B-cell lymphoma-2; ROS, Reactive oxygen species; FADD, Fas-associated death domain; c-FLIP, Cellular FLICE-like inhibitory protein; Apaf-1, Apoptotic protease activating factor 1; ATP, Adenosine triphosphate; BID, BH3 interacting-domain death agonist.
Results of some preclinical experiments on the study of the therapeutic effect of curcumin in tumors.
| Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|
| Breast cancer |
| ROS/YAP1/JNK signaling pathway | Suppresses tumor growth and metastasis. Induces tumor cell apoptosis |
|
| Gastric cancer |
| Gli1-β-catenin | Decreases cellular migration and invasion, while enhances tumor cells apoptosis. Induces cytoskeletal remodeling and inhibits the epithelial-mesenchymal transition process |
|
| Colorectal cancer |
| TFAP2A-mediated ECM pathway: GP1BB, COL9A3, COMP, AGRN, ITGB4, LAMA5, COL2A1, ITGB6, ITGA1, and TNC | Inhibits tumorsphere formation, decreases cell viability in a dose-dependent manner, and promote apoptosis |
|
| Colorectal cancer |
| p53, p21, BAX, BCL-2, and NOXA | Suppresses the proliferation of cancer cells via induction of apoptosis |
|
| Ovarian cancer |
| circ-PLEKHM3/miR-320a/SMG1 axis | Suppresses cancer cell proliferation and promote apoptosis |
|
| Papillary thyroid cancer |
| MMP-2, MMP-9, miR-301a-3p/JAK/STAT3 axis | Inhibits the viability, migration and invasion |
|
| Glioblastoma |
| AKT pathway, Bcl-2 | Anti-proliferation effect, suppresses the growth of tumor and reduces of apoptosis |
|
| Medulloblastoma |
| HDAC | Induce apoptosis and cell cycle arrest at the G2/M phase. Reduces tumor growth and significantly increases mouse survival |
|
ROS, reactive oxygen species; YAP1, yes-associated protein 1; JNK, c-Jun N-terminal kinases; Gli1, GLI family zinc finger 1; TFAP2A, transcription factor AP-2 alpha; ECM, extracellular matrix; GP1BB, glycoprotein Ib (platelet), beta polypeptide; COL9A3, collagen type IX alpha 3 chain; COMP, cartilage oligomeric matrix protein; AGRN, agrin; ITGB4, integrin subunit beta 4; LAMA5, laminin subunit alpha-5; COL2A1, collagen type II alpha 1 chain; ITGB6, integrin subunit beta 6; ITGA1, integrin alpha-1; TNC, tenascin C; BAX, Bcl-2 associated X-protein; BCL-2, B-cell lymphoma-2; NOXA, phorbol-12-myristate-13-acetate-induced protein 1; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; JAK, janus kinase 2; STAT3, signal transducer and activator of transcription 3; HDAC, histone deacetylase 1.
Results of some preclinical experiments on the study of the therapeutic effect of carnosic acid in tumors.
| Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|
| Neuroblastoma |
| PI3K/Akt/Nrf2/γ-GCL/GSH axis | Promotes mitochondrial protection |
|
|
| Nrf2 | Promotes mitochondrial protection and pro-apoptotic stimulus |
| |
|
| PI3K/Akt/Nrf2 axis | Promotes mitochondrial protection, suppresses mitochondria-related pro-oxidant and mitochondria-dependent pro-apoptotic effects of chlorpyrifos |
| |
| Pulmonary adenocarcinoma |
| Dexamethasone-(C21- phosphoramidate)-[anti-EGFR] | Anti-neoplastic cytotoxicity |
|
| Lung cancer |
| PUMA | Cytotoxic activity, cell cycle arrest at G0/G1 and G2/M phases, and anti-apoptotic, effects |
|
|
| iNOS2, Arg-1, and MMP-9 | Anti-growth and pro-apoptotic effects |
| |
| Breast cancer |
| PI3K/AKT/mTOR, CDKN1A/p21WAF1 and CDKN1B/p27KIP1 signaling pathways | Late autophagy and causes derangement of the lysosomal compartment |
|
| Oral squamous cell carcinoma |
| Bax, Bad, Caspase-3 and -9, PARP1, Bcl-2 | Inhibits the tumor growth without affecting the body weight and tissue morphology |
|
| Glioma |
| Cyclin B1, PARP, caspase-3, p-AKT, p62, LC3-I, and LC3-II | Enhances TMZ-induced inhibition of colony formation and cell migration and enhances TMZ-induced cell cycle arrest and cellular apoptosis |
|
| Hepatocellular carcinoma |
| AMPK | Suppresses cell proliferation and reduce cell viability |
|
| Chronic myeloid leukemia |
| miR-780 | Induction of apoptosis and cell cycle arrest |
|
| Melanoma |
| Src, FAK, and AKT | Suppresses the adhesion of tumor cells, as well as the secretion of MMP-9, TIMP-1, uPA, and VCAM-1. Inhibits of the epithelial-mesenchymal transition |
|
| Prostate cancer |
| PERK, ATF-6 and IRE1α | Inhibits tumor growth |
|
| Colon cancer |
| p53, Bax, Mdm2, Bcl-2, and Bcl-xl, caspase-9, and -3, PARP, JAK2, Src kinases, STAT3, cyclin D1, D2, and D3 | Induces apoptosis, inhibits the constitutive phosphorylation, inhibits cell viability and the expression of cyclin D1 and surviving |
|
PI3K, phosphoinositide 3-kinases; γ-GCL, γ-glutamate—cysteine ligase; GSH, glutathione; Nrf2, nuclear factor erythroid 2-related factor 2; EGFR, epidermal growth factor receptor; PUMA, p53 upregulated modulator of apoptosis; iNOS2, nitric oxide synthase 2; Arg-1, arginase 1; MMP-9, matrix metallopeptidase 9; mTOR, mammalian target of rapamycin; CDKN1A, cyclin-dependent kinase inhibitor 1A; CDKN1B, cyclin-dependent kinase inhibitor 1B; p27KIP1, p27; Bax, Bcl-2 associated X-protein; Bad, BCL2-associated agonist of cell death; PARP1, Poly [ADP-ribose] polymerase 1; Bcl-2, B-cell lymphoma-2; PARP, poly(ADP-Ribose) polymerase 1; p-AKT, phospho-Akt; LC3-I, microtubule-associated protein 1A/1B-light chain 3-I; LC3-II, microtubule-associated protein 1A/1B-light chain 3-II; AMPK, AMP-activated protein kinase; Src, proto-oncogene tyrosine-protein kinase Src; FAK, focal adhesion kinase; PERK, protein kinase R (PKR)-like endoplasmic reticulum kinase; ATF-6 a, activating transcription factor 6; Mdm2, mouse double minute 2; Bcl-xl, B-cell lymphoma-extra large; JAK2, janus kinase 2; TMZ, temozolomide; TIMP-1, tissue inhibitor of metalloproteinase 1; uPA, urokinase plasminogen activator; VCAM-1, vascular cell adhesion molecule 1.
The antitumor effects of flavonoids through control the expression inflammation mediators.
| Flavonoids | Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|---|
| Quercetin | Lung cancer |
| NF-κB | Induce tumor cell apoptosis |
|
| Luteolin | Lung cancer |
| NF-kB (p65) | Induce TNF-mediated apoptotic cell death |
|
| EGCG | Lung cancer |
| AP-1, MAPK, NF-κB, and COX-2 | Inhibits tumor growth and metastasis |
|
| Genistein | Gastric cancer |
| NF-κB/COX-2 | Inhibits angiogenesis and metastasis. Suppresses mortality, tumor number, tumor burden and chemical-induced inflammatory responses | ( |
| Quercetin | Colorectal cancer |
| NF-κB | Induce tumor cell apoptosis |
|
| Naringenin | Colorectal cancer |
| NF-κB/p65 | Induce apoptosis and cell cycle arrest |
|
| Xanthohumol | Liver cancer |
| NF-κB/p53 | Induce apoptosis, modulating the NF-κB/p53 and the Notch1 signaling pathways |
|
| Xanthohumol | Cervical cancer |
| NF-κB | Decrease expression of CXCR4, inhibits cell invasion induced by CXCL12 |
|
| Apigenin | Prostate cancer |
| NF-κB/Akt | Induce apoptosis, inhibits cell invasion, motility |
|
| Apigenin | Breast cancer |
| NF-κB | Reduce TNF-α and IL-1β expression |
|
EGCG, epigallocatechin-3-gallate; IL-1β, interleukin -1β; NF-κB, nuclear and cytoplasmic nuclear factor kappa B; TNF-α, tumor necrosis factor-alpha; MAPK, mitogen-activated protein kinase; COX-2, cyclooxygenase 2; AP-1, activating protein-1; CXCR4, C-X-C chemokine receptor type 4; CXCL12, chemokine (C-X-C motif) ligand 12.
The antitumor effects of flavonoids by regulation the expression of TRAIL-induced apoptosis.
| Flavonoids | Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|---|
| Irigenin | Gastric cancer |
| Caspase-8/-9/-3, PARP, FADD, DR5, Bax, c-FLIP, Bcl-2 and Survivin | Reduce tumor growth and suppresses tumor progression |
|
| 2-(3-hydroxyphenyl)-5-methylnaphthyridin-4-one (CSC-3436) | Triple-negative breast cancer |
| c-FLIPS/L, Bcl-Xl, Bcl-2, Survivin, XIAP, and ROS/p38/C/EBP- CHOP signaling pathway | Sensitizes of tumor cell to chemotherapy |
|
| Icariin | Colon cancer |
| ROS, ERK and CHOP | Sensitizes of tumor cell to chemotherapy and reduce tumor growth |
|
| Luteolin | non-small cell lung cancer |
| DR5 and Drp1 | Sensitizes of tumor cell to chemotherapy |
|
| 2'-hydroxy-4-methylsulfonylchalcone (RG003) | Prostate cancer |
| Bcl-2, PI3K/Akt, NF-κB, and COX-2 | Increases poly-ADP-ribose polymerase cleavage and DNA fragmentation. Reduces inflammation and stimulate of apoptosis |
|
| Morusin | Glioblastoma |
| EGFR, DR5, Survivin, XIAP, PDFGR, STAT3 | Decreases cell viability and increases apoptosis |
|
| EGCG | Nasopharyngeal carcinoma |
| Bcl-XL, Bcl-2, FADD, c-FLIP, caspase-8/-9/-3, p65, NF-κB, XIAP and Survivin | Modulate of intrinsic and extrinsic apoptotic pathways |
|
| Galangin | Renal carcinoma |
| NF-κB, Bcl-2, c-FLIP, Mcl-1 and Survivin | Increases apoptosis and tumor growth |
|
EGCG, epigallocatechin-3-gallate; PARP, poly (ADP-ribose) polymerase; FADD, FAS-associated protein with death domain; DR5, death receptor 5; c-FLIP, cellular-FLICE inhibitory protein; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-Xl, B-cell lymphoma-extra-large; XIAP, X-linked inhibitor of apoptosis protein; ROS, reactive oxygen species; CHOP, C/EBP-homologous protein; ERK, extracellular signal-regulated kinase; DR5, death receptor 5; Drp1, dynamin-related protein 1; PI3K, phosphoinositide 3-kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; COX-2, cyclooxygenase-2; EGFR, epidermal growth factor receptor; PDFGR, platelet-derived growth factor receptor alpha; STAT3, signal transducer and activator of transcription 3; FADD, FAS-associated death domain protein; Mcl-1, myeloid-cell leukemia 1.
The antitumor effects of flavonoids by regulation of receptor tyrosine kinases (RTKs) and integrins.
| Flavonoids | Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|---|
| Luteolin | Non-small cell lung cancer |
| Tyro3, Axl and MerTK | Anti-proliferative effect |
|
| EGCG | Lung cancer |
| Axl | Inhibits stemness and tumourigenicity |
|
| Apigenin | Non-small cell lung cancer |
| Axl, p21 and XIAP | Anti-proliferative effect |
|
| Quercetin and luteolin | Pancreatic cancer |
| FAK, PTK, EGFR, and MMP | Suppresses of invasive potential and cell migration. Induce apoptosis |
|
| Apigenin | Ovarian cancer |
| IL-6, STAT3, Bcl-xl, and Axl | Inhibits of apoptosis and tumor cells proliferation |
|
| Quercetin | Glioblastoma |
| Axl, IL-6 and STAT3 | Induces apoptosis |
|
| Genistein and biochanin A | Prostate cancer |
| EGF | Inhibits the tumor growth |
|
| EGCG | Colorectal cancer |
| VEGFR, HIF-1alpha, IGF-1/2, epidermal growth factor (EGF), and heregulin | Inhibits of angiogenesis |
|
EGCG, epigallocatechin-3-gallate; MerTK, myeloid-epithelial-reproductive tyrosine kinase; XIAP, X-linked inhibitor of apoptosis protein; FAK, focal adhesion kinase; PTK, protein tyrosine kinases; EGFR, epidermal Growth Factor Receptor; MMP, matrix metalloproteinases; IL-6, interleukin-6; STAT3, signal transducer and activator of transcription 3; Bcl-xl, B-cell lymphoma-extra large; EGF, epidermal growth factor; VEGFR, vascular endothelial growth factor; HIF-1alpha, hypoxia-inducible factor 1-alpha; IGF-1/2, insulin-like growth factor 1/2; EGF, epidermal growth factor.
The antitumor effect of flavonoids by regulation of integrins.
| Flavonoids | Tumor type | Study model | Gene-targets | Mechanism of action | References |
|---|---|---|---|---|---|
| Pristimerin | Triple-negative breast cancer |
| E-cadherin, N-cadherin and integrin β3 | Inhibits tumor growth and EMT reversion |
|
| Deguelin | Non-small cell lung cancer |
| CtsZ/FAK/Src/Paxillin and integrin β3 | Anti-metastatic effect |
|
| Baicalein | Gastric cancer |
| miR-7/FAK/AKT signaling pathway | Inhibits cell proliferation, metastasis and angiogenesis |
|
| Erybraedin A | Non-small-cell lung cancer |
| Integrin β1, integrin β3 and Src | Block the Src-mediated adhesion and survival of tumor cells |
|
| Silibinin | Prostate cancer |
| Integrins (α5, αV, β1 and β3), FAK, Src, GTPases, ARP2 and cortactin, cPARP, caspase 3), E-cadherin, β-catenin, survivin, and Akt | Inhibits tumor cells motility, invasiveness and survival |
|
| Luteolin | Non-small cell lung cancer |
| Integrin β1 and FAK | Inhibits hypoxia-induced proliferation, motility and adhesion in the cells |
|
| Silibinin | Highly metastatic human breast cancer |
| β1-integrin, Raf-1, Cdc42 and D4-GDI | Inhibits proliferation, migration and adhesion of tumor cells |
|
| EGCG | Medulloblastoma |
| α2-integrin, α3-integrin and β1-integrin | Inhibits cell invasion |
|
EGCG, epigallocatechin-3-gallate; CtsZ, cathepsin Z; FAK, focal adhesion kinase; ARP2, actin related protein 2; cPARP, cleaved poly-ADP ribose polymerase; Cdc42, cell division cycle 42; D4-GDI, D4-guanine diphosphate (GDP)–dissociation inhibitor (GDI).
FIGURE 5Targets and processes affected by some natural polyphenolic compounds in viral infections. This scheme shows the possible mechanisms of the antiviral action of the main classes of natural polyphenolic compounds. Flavonoids have been found to inhibit merger, integration, and reverse transcription. Inhibition of protease, reverse transcriptase, replication and maturation are among the anti-HIV mechanisms of some terpenoids. Coumarins inhibit transcriptase and activation of nuclear factor-kappa B (NF-kB). Note: PGC-1α, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; TLR-3, Toll-like receptor 3; TLR-7, Toll-like receptor 7; ErbB1, Receptor tyrosine-protein kinase; CCR5, C-C chemokine receptor type 5; CXCR4, C-X-C chemokine receptor type 4.
List of polyphenols with antiviral activity.
| Polyphenols | Virus type | Targets/signaling pathways | Mechanism of action | References |
|---|---|---|---|---|
| Resveratrol | Human herpesvirus 1 and Human herpesvirus 2 | ND | Significantly reduced skin lesions, and the effectiveness of the drug depended on its concentration, the time of initiation of treatment and the number of applications per day | ( |
| Epigallocatechin-3-gallate | Hepatitis C Virus | E1/E2 | Inhibition of virion attachment |
|
| Epigallocatechin-3-gallate | Hepatitis C Virus | GT3a and NS3 helicase | Binding interaction of virus NS3 helicase active pocket |
|
| Epigallocatechin-3-gallate | Hepatitis B Virus | HBsAg, HBeAg and virus DNA | Strong anti-HBV activity through decreasing the secretion of HBsAg, HBeAg and extracellular HBV DNA, although perhaps in such a way that the mechanism may interfere with the replication cycle of HBV DNA |
|
| Resveratrol | Human papillomavirus | p-pRb1, p53, virus E6 and E7 genes | Inhibits cervical cancer development by suppressing the transcription and translation of E6 and E7, and also by promoting the apoptosis and G1/S phase transition arrest. |
|
| 6-Gingerol | Human papillomavirus | p53, p21, caspase-3 and PARP | Inhibits the chymotrypsin activity of proteasomes; induce reactivation of p53, and DNA damage and G2/M cell cycle arrest; increases levels of p21; and potentiates the cytotoxicity of cisplatin. |
|
| Resveratrol | Epstein-Barr virus | Rta, Zta, and EA-D | Inhibits virus lytic cycle |
|
GT3a, genotype 3a; NS3, nonstructural protein 3; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e-antigen; p-pRb1, phosphorylated retinoblastoma protein; PARP, Poly (ADP-ribose) polymerase; HBV, Hepatitis B Virus; ND, not mentioned.